sildenafil
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
4161
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
December 12, 2025
In vitro and computational evaluation of the erectogenic and anti-diabetic potential of ethanol extract of Hymenodictyon pachyantha stem bark.
(PubMed, In Silico Pharmacol)
- "Our data revealed that EHP inhibited PDE-5 (IC50 = 0.58 mg/ml), arginase (IC50 = 0.57 mg/ml), and AchE (IC50 = 0.48 mg/ml), comparable with the reference drug, sildenafil (IC50 = 0.55 mg/ml). The results also showed that EHP inhibited α-amylase (IC50 = 0.81 mg/ml) and α-glucosidase (IC50 = 0.23 mg/ml) compared with the reference drug acarbose, which showed IC50 = 0.66 mg/ml and 0.25 mg/ml, respectively...Overall, our findings showed that EHP inhibited PDE-5, arginase, AchE, α-amylase, and α-glucosidase, with phytochemicals particularly rutin, naringin, catechin, and sapogenin showing the strongest docking affinities and favorable ADMET properties, indicating that EHP contains compounds with erectogenic and antidiabetic potentials; however, further research is required to confirm the safety and efficacy of EHP's phytocompounds using in vivo experiments. The online version contains supplementary material available at..."
Journal • Preclinical • Diabetes • Erectile Dysfunction • Metabolic Disorders • Pain
December 12, 2025
Mechanistic study of PDE5A inhibitors from the prepared folium of Epimedium sagittatum maxim.
(PubMed, J Struct Biol)
- "Further structural analyses revealed distinct binding modes adopted by 1 and 5 for occupying the PDE5A active site, highlighting their specific interactions with PDE5A compared to each other and to other established inhibitors like sildenafil. In summary, these findings underscore the potential of PFES-derived natural compounds as specific PDE5A inhibitors, and provide crucial insights for the rational development of novel ED therapeutics with potentially improved specificity and reduced side effects based on TCM constituents."
Journal • Erectile Dysfunction
December 11, 2025
Persistent Pulmonary Hypertension in Corrected Congenital Left Circumflex Artery to Coronary Sinus Fistula: A Case Report and Literature Review.
(PubMed, Case Rep Cardiol)
- "Postoperatively, the patient remained symptomatic, with elevated pulmonary arterial pressure persisting, prompting the initiation of triple therapy comprising macitentan, selexipag, and sildenafil. The case illustrates a rare case of persistent PHTN in a corrected LCx-CS fistula. Thorough follow-up, early diagnosis, and timely interventions, complemented by pharmacotherapy when necessary, are essential in managing these complex clinical scenarios."
Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
December 11, 2025
Cerebral, Muscle and Blood Oxygenation in Patients with Pulmonary Vascular Disease Whilst Breathing Normobaric Hypoxia vs. Normoxia Before and After Sildenafil: Data from a Randomised Controlled Trial.
(PubMed, J Clin Med)
- " In PVD patients, acute exposure to normobaric hypoxia leads to a reduction in arterial oxygenation as well as cerebral and muscular tissue oxygenation. Sildenafil improves cerebral blood flow but has no effect on arterial, cerebral or muscular oxygenation."
Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases
December 10, 2025
Spatial and Temporal Tracking of Counterfeit Phosphodiesterase Type V Inhibitors Use Based on Wastewater Analysis.
(PubMed, Environ Sci Technol)
- "Among the three target compounds, neither tadalafil nor vardenafil was detected in any sample. Sildenafil, however, was found in 94.5% of the samples, with concentrations ranging from below the limit of quantification (LOQ) to 75.4 ng/L...Subpopulation analysis further revealed that college students (38.5 mg/d/1000 inh) and island residents (28.6 mg/d/1000 inh) had lower levels of use compared to the general population (85.1 mg/d/1000 inh). These results highlight the potential of wastewater-based drug surveillance in tracking consumption trends of nonprescribed and counterfeit pharmaceuticals, offering robust evidence to inform regulatory efforts and improve public risk perception."
Journal • Erectile Dysfunction
December 10, 2025
Upfront combination therapy with sildenafil and ambrisentan in patients with chronic thromboembolic pulmonary hypertension.
(PubMed, J Bras Pneumol)
- "The combined use of sildenafil and ambrisentan appears to be associated with clinical, functional, and hemodynamic improvement in patients with CTEPH."
Journal • Retrospective data • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Pulmonary Embolism • Respiratory Diseases
December 05, 2025
Case Report: Concurrent atrial and ventricular septal defect in a young Sphynx cat.
(PubMed, Front Vet Sci)
- "Initial treatment with furosemide and supplemental oxygen led to clinical improvement...Medical management with phlebotomy, sildenafil, clopidogrel, and oxygen supplementation provided temporary stabilization; however, the cat eventually died approximately 1 year after diagnosis, likely due to disease progression and inconsistent therapeutic compliance...Histopathological examination revealed pulmonary vascular remodeling and myocardial fibrosis, indicative of chronic pulmonary hypertension. This report represents the first documented case of concurrent ASD and VSD with Eisenmenger physiology in a cat, with long-term clinical follow-up and postmortem confirmation."
Journal • Cardiovascular • Fibrosis • Heart Failure • Hematological Disorders • Hypertension • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
December 05, 2025
PDE-5 inhibitors in complex matrices: Recent updates on pretreatment and detection methods.
(PubMed, J Chromatogr A)
- "Common medications include sildenafil, tadalafil, and vardenafil. Among these, the use of high-resolution mass spectrometry is a current research hotspot. The review critically evaluates the advantages and limitations of existing methodologies, identifies future development directions, and supports the selection of efficient analytical strategies for specific sample matrices and research purposes."
Journal • Review • Erectile Dysfunction
December 03, 2025
Exploring dual inhibitors Carbonic Anhydrases and Phosphodiesterase 5 as potential agents for treatment Alzheimer's disease.
(PubMed, Eur J Med Chem)
- "Moreover, compound 8a demonstrated a favourable safety profile, as it did not markedly impair cell viability on differentiated SH-SY5Y at concentrations up to 100 μM and conferred protection against Aβ-induced cytotoxicity showing superior efficacy compared to the single-target reference agents acetazolamide (AAZ) and sildenafil in mitigating oxidative stress. In vivo, chronic administration of compound 8a prevented deficits in both recognition and working memory in Aβ1-42-infused mice, outperforming vehicle-treated controls. Collectively, these findings highlight the potential of dual CA/PDE5 inhibition as a novel therapeutic strategy for Alzheimer's disease."
Journal • Alzheimer's Disease • CNS Disorders
December 01, 2025
When Erectile Dysfunction Therapy Clouds the Vision: ST-BRVO after Sildenafil in a Healthy Male.
(PubMed, Case Rep Ophthalmol)
- "The patient was treated with an intravitreal injection of bevacizumab, leading to anatomical and visual improvement. The temporal proximity and absence of systemic risk factors suggest a potential dose-independent vascular susceptibility. Clinicians should be aware of this rare but potentially vision-threatening complication."
Journal • Erectile Dysfunction • Hematological Disorders • Macular Edema • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain • Retinal Disorders • Retinal Vein Occlusion
December 02, 2025
Sex differences in sildenafil-induced migraine attacks: Results from a double-blind, placebo-controlled provocation study
(EHF-EHC 2025)
- "These findings could reflect biological differences in migraine pathophysiology and support the importance of considering sex as a factor in provocation model design. Final data from the male cohort will be presented at the conference."
Clinical • CNS Disorders • Migraine • Pain
December 01, 2025
A Systematic Literature Review Exploring the Efficacy and Safety of Tadalafil and Sildenafil in Pulmonary Arterial Hypertension.
(PubMed, Pulm Circ)
- "Two studies reported patients who switched from sildenafil to tadalafil treatment, treatment transition was feasible. Although comparable when used as monotherapy, this qualitative analysis suggests that tadalafil + ERA combination therapy may have more favorable 6MWD improvements than sildenafil + ERA combination therapy."
Journal • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
December 01, 2025
Discovery of natural PDE-5 inhibitors in NO signalling pathways for the human erectile dysfunction management: a multi-layered in silico assessment.
(PubMed, In Silico Pharmacol)
- "The phytochemicals Daidzin, Maackiain, Rutecarpin, and Cyclopamine exhibited strong binding affinity with PDE-5, supported by stable MD simulations and favourable MM/PBSA energies. All compounds have shown comparably equal results with Sildenafil. The online version contains supplementary material available at 10.1007/s40203-025-00491-6."
Journal • Erectile Dysfunction
November 28, 2025
Pulmonary hypertension associated with COVID-19-interstitial lung disease
(BTS WM 2025)
- "Following ILD-PH diagnosis, 4 patients were treated with sildenafil...Download figure Open in new tab Download powerpoint Abstract P283 Figure 1 Conclusion Post Covid-ILD-PH was only seen in patients after prolonged invasive mechanical ventilation and is likely to be a rare complication of COVID-19. All patients had elevated BNP, and RV:LV and/or PA:aortic ratio on unenhanced CT scans: these non-invasive screening markers should prompt referral for echocardiography and onwards to PH centres."
Cardiovascular • Infectious Disease • Interstitial Lung Disease • Novel Coronavirus Disease • Pneumonia • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
November 27, 2025
Efficacy and Safety of Sildenafil in Combination with Dapagliflozin Versus Dapagliflozin Monotherapy in the Management of Heart Failure with Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
(PubMed, Pharmaceuticals (Basel))
- " Addition of sildenafil to dapagliflozin did not demonstrate any significant clinical or hemodynamic benefit over dapagliflozin monotherapy in HF patients and PH-LHD. Further studies are warranted to evaluate the effects over the long term."
Journal • Monotherapy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
November 27, 2025
Integrative Approaches to Ovulation Induction in Polycystic Ovary Syndrome: A Narrative Review of Conventional and Complementary Therapies.
(PubMed, Biomedicines)
- "This narrative review summarizes the current evidence for ovulation induction in patients with PCOS, including conventional pharmacologic agents, such as clomiphene citrate, letrozole, gonadotropins, and insulin-sensitizing agents, as well as complementary therapies, such as acupuncture and Chinese herbal medicine. We also examine emerging adjuvants, such as vitamin D, omega-3 fatty acids, sildenafil, and antioxidants that may enhance clinical pregnancy rates or improve endometrial receptivity. While robust evidence supports the use of letrozole as a first-line agent, complementary and integrative therapies may offer additional benefits, particularly in treatment-resistant or preference-driven contexts. Further high-quality studies are needed to clarify the role of combined therapeutic strategies in optimizing fertility outcomes for women with PCOS."
Journal • Review • Infertility • Polycystic Ovary Syndrome • Sexual Disorders
November 27, 2025
Off-Label Sildenafil Citrate as a Rescue Therapy for Areolar Venous Congestion Post-Breast Reduction: Case Series and Outcomes.
(PubMed, Life (Basel))
- "Its favorable safety profile, widespread hospital availability, and mechanism of enhancing microvascular circulation make it a promising adjunct in managing this complication. Further studies are warranted to standardize its use and determine its place within a broader postoperative management spectrum of compromised vascularization in breast surgery."
Journal
November 25, 2025
Dual one-step LC-MS/MS methods for hair analysis in drug-facilitated crime: application to an alleged Fraud-Related case.
(PubMed, Forensic Sci Med Pathol)
- "This study aimed to develop and validate two simplified, one-step extraction methods coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the simultaneous segmental analysis of psychoactive substances, specifically doxylamine (DOX), haloperidol (HAL), citalopram (CTP), sildenafil (SDF), and common illicit drugs in hair samples. Segmental hair analysis provided critical retrospective evidence, reinforcing its value in complex DFC investigations. The interpretation remained confined to analytical evidence, without inferring intent."
Journal • CNS Disorders • Psychiatry
November 25, 2025
Umbilical Cord Mesenchymal Stem Cell Secretome Administration in Severe Erectile Dysfunction Non-responsive to Sildenafil
(clinicaltrials.gov)
- P=N/A | N=12 | Completed | Sponsor: Indonesia University
New trial • Diabetes • Erectile Dysfunction • Metabolic Disorders • Type 2 Diabetes Mellitus
November 24, 2025
Appreciation of Increased Pulmonary Vascular Resistance from the Maximum Desaturation in 2-Chair Test: An Appraisal.
(PubMed, Int J Chron Obstruct Pulmon Dis)
- "The desat max of 2-chair test, claimed to have identified the sildenafil responsiveness in COPD-PH (pulmonary hypertension), should represent high PVR (pulmonary vascular resistance)...Desat-max of 2-chair test appears indicative of high PVR in CLD-PH. The revelation merits further research."
Clinical • Journal • Asthma • Cardiovascular • Chronic Obstructive Pulmonary Disease • Hypertension • Immunology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
November 24, 2025
Sildenafil suppresses the activation of hypertrophic scar fibroblasts by promoting the KLF15-mediated inhibition of LOXL1 transcription.
(PubMed, Korean J Physiol Pharmacol)
- "LOXL1 silencing abrogated the effect of KLF15 knockdown on SIL-inhibited proliferation, migration, and ECM deposition. SIL inhibited the transcriptional activity of LOXL1 by upregulating KLF15, eventually inactivating SMAD signaling and suppressing the proliferation, migration, and ECM deposition of HSFbs."
Journal • Fibrosis • Immunology • Pain • KLF5
November 23, 2025
Idiophatic Pulmonary Hypertension in Children Mongolia: A Case Report
(APSR 2025)
- "The treatment was initiated with furosemide (1 mg/kg/day) and captopril (1 mg/kg/d) in 1 year and sildenafil (1 mg/kg/d) was combined in last 5 months. 2 case was diagnosed during pathoanatomy section, 5 case diagnosed alive and 3 of them died althouth treated with combination therapy. 2 of them are still alive."
Case report • Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases
November 20, 2025
SPARC: Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment
(clinicaltrials.gov)
- P2/3 | N=30 | Not yet recruiting | Sponsor: The University of Texas Medical Branch, Galveston | Initiation date: Oct 2025 ➔ Mar 2026
Trial initiation date • Cognitive Disorders • Oncology
November 20, 2025
Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database.
(PubMed, Eur Urol Focus)
- "PDE5i usage is associated with distinct efficacy and AE profiles in a large real-world dataset guiding treatment recommendations for urologists. Future DTC data might be used to complement clinical trial data."
Head-to-Head • Journal • Erectile Dysfunction
November 19, 2025
The impacts of L-citrulline and sildenafil on penile and testicular vascular perfusion pattern, advanced testicular analysis, steroids, and semen picture in normospermic dogs.
(PubMed, Vet Res Commun)
- "An elevation of nitric oxide and estradiol levels was observed (P = 0.01) form 1 h in L-Cit + S group compared to other groups, while testosterone levels were increased (P = 0.01) from 1 h but rapidly declined till reach a lowest value at 48 h compared to other groups. Addition of L-citrulline to sildenafil demonstrated a more efficiency in improvement of blood flow, hormonal profile, and semen quality than using sildenafil alone due to the action of L-Cit on nitric oxide."
Journal
1 to 25
Of
4161
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167